Close Menu

NEW YORK – Agilent Technologies announced today that it has priced an underwritten, registered public offering of a series of its senior notes, in an aggregate principal amount of $500 million.

In a filing with the US Securities and Exchange Commission, the company said that the notes will mature in September 2029 and will bear interest at an annual rate of 2.750 percent. The offering is expected to close on Sep. 16, and Agilent is expecting net proceeds of approximately $492.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.